Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio™) is a clinical-stage biopharmaceutical company pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ targeting oncology and immuno-dysregulated diseases. Our lead asset, IMX-110, is currently in phase 1b/2a clinical trials for solid tumors in the United States and Australia. Our proprietary System Multi-Action RegulaTors SMARxT Tissue-Specific Platform produces drugs that accumulate at intended therapeutic sites at 3-5 times that of conventional medicines. Our TME Normalization™ Technology allows our drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the tumor micro-environment, or TME. We have uncovered fundamental biological systems that link oncology and inflammation. Our pipeline includes pre-clinical tissue-specific therapeutics to treat inflammatory bowel disease, including ulcerative colitis and Crohn’s disease.

Mesa Verde Venture Partners

Immix Biopharma (Nasdaq: IMMX)

Immix Biopharma Announces Complete Response in 9th Relapsed/Refractory AL Amyloidosis Patient in NXC-201 Clinical Trial at IMS 20th Annual Meeting

Read the press release here: https://loom.ly/1Pu09G0

#cancertreatment #biopharma #sciencenews

Immix Biopharma Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Read the press release here: https://loom.ly/4PQGN9c

#science #biopharma #cancertreatment #multiplemyeloma #car-t

Immix Biopharma Subsidiary Nexcella Completes 2nd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Read the press release here: https://loom.ly/HCKoAzU

#cancertreatment #science #biopharma

Immix Biopharma is pioneering a novel class of Tissue-Specific Therapeutics (TSTx)™ 

Read more here: https://lnkd.in/emdDgvbQ

#science #cancertreatment #technology

Immix Biopharma's subsidiary Nexcella, Inc. 

Learn more about Nexcella, Inc.: https://nexcella.com/  

#biopharma #cancertreatment #science

Who founded Immix Biopharma?

Read more here: https://lnkd.in/enZ6FH3s 

#science #cancer #biopharma

Nexcella, Immix Biopharma Subsidiary, to Present at the Bank of America 2023 Healthcare Trailblazers Private Company Conference

#healthcare #science #biopharma

Dr. Suzanne Lentzsch Joins Immix Biopharma Scientific Advisory Board

Read the press release here: https://loom.ly/spWfYjU

#sciencenews #biopharma

FDA Orphan Drug Designation (“ODD”) qualifies NXC-201 for the following: 

Read the press release here: https://loom.ly/fwrLYNQ

#fda #science #cancer

U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Read the press release here: https://loom.ly/fwrLYNQ 

#science #biopharma #sciencenews

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				-89.52M -
cost of revenue					5.47K -
gross profit				-89.52M -	-5.47K 99.99%
selling and marketing expenses					-6.46K -
general and administrative expenses	259.34K -	205.70K 20.68%	1.23M 495.76%	4.02M 228.29%	7.41M 84.09%
selling general and administrative expenses	259.34K -	205.70K 20.68%	1.23M 495.76%	4.02M 228.29%	7.40M 83.93%
research and development expenses	583.16K -	248.15K 57.45%	126.53K 49.01%	4.20M 3,216.11%	8.74M 108.19%
other expenses	224 -	512 128.57%
cost and expenses	842.50K -	453.85K 46.13%	1.35M 197.90%	8.22M 507.90%	16.14M 96.38%
operating expenses	842.50K -	453.85K 46.13%	1.35M 197.90%	8.22M 507.90%	16.13M 96.31%
interest expense	109.98K -	101.98K 7.28%	179.85K 76.37%	497 99.72%
ebitda	-841.19K -	-451.02K 46.38%	-1.35M 199.22%	-8.22M 508.86%	-16.13M 96.36%
operating income	-842.50K -	-453.85K 46.13%	-1.35M 197.90%	-8.22M 507.90%	-16.14M 96.38%
depreciation and amortization	1.31K -	2.83K 116.92%	2.47K 12.88%	2.13K 13.49%	5.47K 156.11%
total other income expenses net	-109.76K -	-676.46K 516.31%	-23.03M 3,303.85%	-497 100.00%	571.01K 114,991.95%
income before tax	-952.26K -	-1.13M 18.70%	-24.38M 2,056.73%	-8.22M 66.28%	-15.57M 89.42%
income tax expense	20.55K -	17.55K 14.62%	6.01K 65.73%	10.27K 70.76%	26.41K 157.26%
net income	-972.81K -	-1.15M 17.99%	-24.38M 2,024.28%	-8.23M 66.25%	-15.43M 87.44%
weighted average shs out	8.44M -	8.77M 3.94%	3.67M 58.15%	13.89M 278.13%	17.34M 24.87%
weighted average shs out dil	8.44M -	8.77M 3.94%	3.67M 58.15%	13.89M 278.13%	17.34M 24.87%
eps	-0.12 -	-0.13 8.33%	-6.64 5,007.69%	-0.59 91.11%	-0.89 50.85%
epsdiluted	-0.12 -	-0.13 8.33%	-6.64 5,007.69%	-0.59 91.11%	-0.89 50.85%

COM:IMMIXBIO

Immix Biopharma, Inc.

Last Close

1.68

22/11 21:00

Market Cap

53.89M

Beta: -

Volume Today

249.22K

Avg: -

Preview